12/11/09 update
Another week when the market didn't feel like it was moving higher, yet actually did. This was true, however, for the overall market but, unfortunately, not for biotechs. What is it with biotechs this year?
At Friday's close, the Nasdaq Composite Index was up 39.37% CYTD, or Contest Year To Date, (vs. up 37.94% CYTD a week ago), while the Nasdaq Biotech Index was up 14.09% CYTD (vs. up 15.24% CYTD a week ago)and the Contest median was up 12.21% CYTD (vs. up 13.54% CYTD a week ago).
There was no change in the Contest's top four, with the week's closing CYTD percentages being: RKRW up 115.12%, NIGEL up 81.64%, GENE up 73.62% and MIKE up 65.81%.
At Friday's close, 19 of the 32 Contest portfolios were in the black and 14 of the 32 were beating the NBI.
Portfolio adjustments: NTII (held only in RKRW's portfolio) paid a $.18 dissolution dividend on 12/9 which I simply added to its share price.
I'm assuming there will be a 2010 Biotech Charity Contest, so biotechies might want to begin thinking about their portfolios.
Have a terrific weekend folks!
Below is the Top Ten list on 12/11/09:
12/11/09
Rank Name Profit/Loss
1 RKRW 115,124
2 NIGEL 81,639
3 GENE 73,622
4 MIKE 65,808
5 GEORGIA 60,372
6 BULBA 49,604
7 SCARAM 47,418
8 BIOFISH 43,741
9 PGO 41,349
10 BIOJIM 36,984
(All corrections, especially adjustments for splits, greatly appreciated.) |
